HER2阳性-话题@MedSci

#HER2阳性#

183篇内容 | 4813人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1308529, encodeId=3a741308529d0, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=妥妥双靶，更久生存——HER2阳性乳腺癌患者强化抗HER2治疗持续获益, objectType=article, longId=156800, objectId=1b161568001d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b161568001d, replyNumber=0, likeNumber=67, createdTime=2018-12-28, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b161568001d, moduleTitle=妥妥双靶，更久生存——HER2阳性乳腺癌患者强化抗HER2治疗持续获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b161568001d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308528, encodeId=fe40130852891, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=曲妥珠单抗多线治疗HER2阳性型晚期乳腺癌1例, objectType=article, longId=156798, objectId=ca5a156e98dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ca5a156e98dd, replyNumber=0, likeNumber=67, createdTime=2018-12-28, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ca5a156e98dd, moduleTitle=曲妥珠单抗多线治疗HER2阳性型晚期乳腺癌1例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ca5a156e98dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308527, encodeId=1048130852e2d, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=邱文生教授：提高HER2阳性胃癌检出率，把握更优治疗时机, objectType=article, longId=155681, objectId=264615568181, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=264615568181, replyNumber=0, likeNumber=55, createdTime=2018-12-14, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=264615568181, moduleTitle=邱文生教授：提高HER2阳性胃癌检出率，把握更优治疗时机, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=264615568181)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308526, encodeId=26ff130852654, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=美例秀秀｜HER2阳性乳腺癌全程管理实践, objectType=article, longId=155649, objectId=6a9415564907, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a9415564907, replyNumber=0, likeNumber=96, createdTime=2018-12-14, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a9415564907, moduleTitle=美例秀秀｜HER2阳性乳腺癌全程管理实践, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a9415564907)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308525, encodeId=5952130852528, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=帕妥珠单抗+曲妥珠单抗双靶新辅助治疗HER2阳性乳腺癌, objectType=article, longId=154864, objectId=cab015486477, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cab015486477, replyNumber=0, likeNumber=0, createdTime=2018-12-02, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cab015486477, moduleTitle=帕妥珠单抗+曲妥珠单抗双靶新辅助治疗HER2阳性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cab015486477)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308524, encodeId=e3411308524b5, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=HER2阳性乳腺癌新辅助治疗思考, objectType=article, longId=154854, objectId=842215485465, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=842215485465, replyNumber=0, likeNumber=77, createdTime=2018-12-02, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=842215485465, moduleTitle=HER2阳性乳腺癌新辅助治疗思考, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=842215485465)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308523, encodeId=99061308523e3, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=美例秀秀｜HER2阳性乳腺癌新辅助治疗思考, objectType=article, longId=154642, objectId=722a154642f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=722a154642f6, replyNumber=0, likeNumber=92, createdTime=2018-12-01, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=722a154642f6, moduleTitle=美例秀秀｜HER2阳性乳腺癌新辅助治疗思考, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=722a154642f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308522, encodeId=5db613085224f, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=美例秀秀｜HER2阳性型转移性乳腺癌治疗病例分享, objectType=article, longId=154460, objectId=6b211544600c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b211544600c, replyNumber=0, likeNumber=88, createdTime=2018-11-28, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b211544600c, moduleTitle=美例秀秀｜HER2阳性型转移性乳腺癌治疗病例分享, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b211544600c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308521, encodeId=7e0413085218c, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=美例秀秀｜HER2阳性乳腺癌伴脑转移患者治疗, objectType=article, longId=153321, objectId=26d1153321b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26d1153321b9, replyNumber=0, likeNumber=72, createdTime=2018-11-14, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26d1153321b9, moduleTitle=美例秀秀｜HER2阳性乳腺癌伴脑转移患者治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26d1153321b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308520, encodeId=9d08130852077, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=J Gastroenterology：HER2变异会对HER2阳性胃癌患者接受曲妥珠单抗疗效产生影响, objectType=article, longId=153292, objectId=0cc015329201, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0cc015329201, replyNumber=0, likeNumber=70, createdTime=2018-11-13, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0cc015329201, moduleTitle=J Gastroenterology：HER2变异会对HER2阳性胃癌患者接受曲妥珠单抗疗效产生影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0cc015329201)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308519, encodeId=f61e1308519fa, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=【2018 SIMOS】HER2专场：PH双靶向治疗引领HER2阳性肿瘤治疗变革, objectType=article, longId=152213, objectId=aa521522136d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa521522136d, replyNumber=0, likeNumber=89, createdTime=2018-10-31, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa521522136d, moduleTitle=【2018 SIMOS】HER2专场：PH双靶向治疗引领HER2阳性肿瘤治疗变革, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa521522136d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308518, encodeId=f2e013085181d, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=病例分享｜首诊IV期伴内脏转移HER2阳性晚期乳腺癌一例, objectType=article, longId=151957, objectId=fd5115195e0b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd5115195e0b, replyNumber=0, likeNumber=63, createdTime=2018-10-28, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd5115195e0b, moduleTitle=病例分享｜首诊IV期伴内脏转移HER2阳性晚期乳腺癌一例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd5115195e0b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308517, encodeId=25a7130851e6b, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=HER2阳性乳腺癌患者可能受益于短程曲妥珠单抗疗法, objectType=article, longId=151496, objectId=80e315149618, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=80e315149618, replyNumber=0, likeNumber=58, createdTime=2018-10-23, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=80e315149618, moduleTitle=HER2阳性乳腺癌患者可能受益于短程曲妥珠单抗疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=80e315149618)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308516, encodeId=0ce41308516e7, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=GUT：HER2阳性转移性胃癌患者曲妥珠单抗耐药机制研究进展, objectType=article, longId=150583, objectId=c84815058345, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c84815058345, replyNumber=0, likeNumber=59, createdTime=2018-10-10, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c84815058345, moduleTitle=GUT：HER2阳性转移性胃癌患者曲妥珠单抗耐药机制研究进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c84815058345)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308515, encodeId=e440130851526, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=HER2阳性晚期乳腺癌伴脑转移一例, objectType=article, longId=149806, objectId=ef87149806e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef87149806e1, replyNumber=0, likeNumber=91, createdTime=2018-09-29, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef87149806e1, moduleTitle=HER2阳性晚期乳腺癌伴脑转移一例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ef87149806e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308514, encodeId=3db1130851440, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=【2018 CSCO】梁寒、袁响林教授分享多学科协作背景下HER2阳性胃癌的诊疗实践与进展, objectType=article, longId=149579, objectId=425a1495e9da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=425a1495e9da, replyNumber=0, likeNumber=86, createdTime=2018-09-27, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=425a1495e9da, moduleTitle=【2018 CSCO】梁寒、袁响林教授分享多学科协作背景下HER2阳性胃癌的诊疗实践与进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=425a1495e9da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308513, encodeId=0796130851330, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Lancet Oncol：曲妥珠单抗+帕妥珠单抗+化疗不能延长HER2阳性转移性胃或胃食管交界癌患者总生存期, objectType=article, longId=148716, objectId=1eac148e167e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1eac148e167e, replyNumber=0, likeNumber=0, createdTime=2018-09-14, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1eac148e167e, moduleTitle=Lancet Oncol：曲妥珠单抗+帕妥珠单抗+化疗不能延长HER2阳性转移性胃或胃食管交界癌患者总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1eac148e167e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308512, encodeId=32d51308512d5, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=吡咯替尼上市，带来HER2阳性晚期乳腺癌患者新选择新希望, objectType=article, longId=147830, objectId=b31f14e83085, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b31f14e83085, replyNumber=0, likeNumber=98, createdTime=2018-09-01, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b31f14e83085, moduleTitle=吡咯替尼上市，带来HER2阳性晚期乳腺癌患者新选择新希望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b31f14e83085)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308511, encodeId=ad181308511f5, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Unum Therapeutics宣布研究性新药（IND）申请：抗体偶联T细胞受体（ACTR）细胞疗法和曲妥珠单抗联合治疗HER2阳性晚期癌症, objectType=article, longId=146626, objectId=e59d146626ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e59d146626ef, replyNumber=0, likeNumber=67, createdTime=2018-08-16, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e59d146626ef, moduleTitle=Unum Therapeutics宣布研究性新药（IND）申请：抗体偶联T细胞受体（ACTR）细胞疗法和曲妥珠单抗联合治疗HER2阳性晚期癌症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e59d146626ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308510, encodeId=71651308510e9, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Lancet oncol：ABP980，曲妥珠单抗的生物类似物，用于HER2阳性的乳腺癌患者的效果和安全性，与曲妥珠单抗的不相上下, objectType=article, longId=140064, objectId=732314006499, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=732314006499, replyNumber=0, likeNumber=61, createdTime=2018-06-07, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=732314006499, moduleTitle=Lancet oncol：ABP980，曲妥珠单抗的生物类似物，用于HER2阳性的乳腺癌患者的效果和安全性，与曲妥珠单抗的不相上下, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=732314006499)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

HER2阳性

2020-05-29

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

妥妥双靶，更久生存——HER2阳性乳腺癌患者强化抗HER2治疗持续获益

2018-12-28

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

曲妥珠单抗多线治疗HER2阳性型晚期乳腺癌1例

2018-12-28

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

邱文生教授：提高HER2阳性胃癌检出率，把握更优治疗时机

2018-12-14

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

美例秀秀｜HER2阳性乳腺癌全程管理实践

2018-12-14

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

帕妥珠单抗+曲妥珠单抗双靶新辅助治疗HER2阳性乳腺癌

2018-12-02

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

HER2阳性乳腺癌新辅助治疗思考

2018-12-02

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

美例秀秀｜HER2阳性乳腺癌新辅助治疗思考

2018-12-01

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

美例秀秀｜HER2阳性型转移性乳腺癌治疗病例分享

2018-11-28

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

美例秀秀｜HER2阳性乳腺癌伴脑转移患者治疗

2018-11-14

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

J Gastroenterology：HER2变异会对HER2阳性胃癌患者接受曲妥珠单抗疗效产生影响

2018-11-13

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

【2018 SIMOS】HER2专场：PH双靶向治疗引领HER2阳性肿瘤治疗变革

2018-10-31

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

病例分享｜首诊IV期伴内脏转移HER2阳性晚期乳腺癌一例

2018-10-28

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

HER2阳性乳腺癌患者可能受益于短程曲妥珠单抗疗法

2018-10-23

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

GUT：HER2阳性转移性胃癌患者曲妥珠单抗耐药机制研究进展

2018-10-10

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

HER2阳性晚期乳腺癌伴脑转移一例

2018-09-29

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

【2018 CSCO】梁寒、袁响林教授分享多学科协作背景下HER2阳性胃癌的诊疗实践与进展

2018-09-27

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Lancet Oncol：曲妥珠单抗+帕妥珠单抗+化疗不能延长HER2阳性转移性胃或胃食管交界癌患者总生存期

2018-09-14

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

吡咯替尼上市，带来HER2阳性晚期乳腺癌患者新选择新希望

2018-09-01

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Unum Therapeutics宣布研究性新药（IND）申请：抗体偶联T细胞受体（ACTR）细胞疗法和曲妥珠单抗联合治疗HER2阳性晚期癌症

2018-08-16

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Lancet oncol：ABP980，曲妥珠单抗的生物类似物，用于HER2阳性的乳腺癌患者的效果和安全性，与曲妥珠单抗的不相上下

2018-06-07

科室
- - 订阅+
  - 更多科室
工具
服务